Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 100,000 shares of the company’s stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $7.43, for a total transaction of $743,000.00. Following the sale, the chief executive officer now directly owns 2,194,789 shares in the company, valued at approximately $16,307,282.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Christopher Richard Anzalone also recently made the following trade(s):
- On Thursday, March 15th, Christopher Richard Anzalone sold 300,000 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $7.43, for a total transaction of $2,229,000.00.
NASDAQ:ARWR opened at $6.37 on Friday. Arrowhead Pharmaceuticals has a fifty-two week low of $1.42 and a fifty-two week high of $8.09. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.87 and a quick ratio of 3.87.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Friday, February 9th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.04). Arrowhead Pharmaceuticals had a negative return on equity of 42.52% and a negative net margin of 116.17%. The company had revenue of $3.51 million during the quarter, compared to analyst estimates of $8.71 million. analysts anticipate that Arrowhead Pharmaceuticals will post -0.71 earnings per share for the current year.
Several research analysts recently commented on the stock. ValuEngine raised shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. B. Riley raised their price target on shares of Arrowhead Pharmaceuticals from $3.00 to $4.00 and gave the stock a “neutral” rating in a research note on Monday, February 12th. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, February 19th. BidaskClub cut shares of Arrowhead Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 14th. Finally, Jefferies Group started coverage on shares of Arrowhead Pharmaceuticals in a report on Tuesday, March 27th. They set a “buy” rating and a $10.00 target price on the stock. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Arrowhead Pharmaceuticals currently has an average rating of “Buy” and an average price target of $6.30.
Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Capital Wealth Advisors purchased a new position in Arrowhead Pharmaceuticals during the 4th quarter worth approximately $119,000. Macquarie Group Ltd. purchased a new position in Arrowhead Pharmaceuticals during the 4th quarter worth approximately $123,000. Jane Street Group LLC purchased a new position in Arrowhead Pharmaceuticals during the 4th quarter worth approximately $130,000. Two Sigma Investments LP purchased a new position in Arrowhead Pharmaceuticals during the 4th quarter worth approximately $146,000. Finally, Dimensional Fund Advisors LP raised its position in Arrowhead Pharmaceuticals by 252.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock worth $192,000 after buying an additional 31,765 shares during the last quarter. 26.88% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Sells 100,000 Shares of Stock” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/08/arrowhead-pharmaceuticals-inc-arwr-ceo-christopher-richard-anzalone-sells-100000-shares.html.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.